OrthoPediatrics Corp. (NASDAQ:KIDS) CEO Sells $164,573.20 in Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) CEO David R. Bailey sold 6,620 shares of the company’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $164,573.20. Following the completion of the transaction, the chief executive officer now owns 319,155 shares in the company, valued at approximately $7,934,193.30. The trade was a 2.03 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

OrthoPediatrics Stock Up 1.8 %

Shares of NASDAQ:KIDS traded up $0.46 during trading on Tuesday, reaching $25.42. The stock had a trading volume of 138,044 shares, compared to its average volume of 162,840. OrthoPediatrics Corp. has a one year low of $21.02 and a one year high of $35.99. The company has a market capitalization of $617.38 million, a P/E ratio of -20.67 and a beta of 1.22. The company has a current ratio of 7.17, a quick ratio of 3.68 and a debt-to-equity ratio of 0.19. The firm’s 50-day simple moving average is $24.74 and its 200 day simple moving average is $25.62.

OrthoPediatrics (NASDAQ:KIDS) last released its quarterly earnings results on Tuesday, March 4th. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. OrthoPediatrics had a negative net margin of 15.00% and a negative return on equity of 5.78%. The business had revenue of $52.67 million for the quarter, compared to analysts’ expectations of $51.16 million. During the same period last year, the business earned ($0.23) EPS. As a group, research analysts expect that OrthoPediatrics Corp. will post -0.93 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have issued reports on KIDS. Stifel Nicolaus dropped their target price on shares of OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, March 5th. Needham & Company LLC reiterated a “buy” rating and set a $42.00 target price on shares of OrthoPediatrics in a report on Wednesday, March 5th. Finally, Truist Financial dropped their target price on shares of OrthoPediatrics from $28.00 to $25.00 and set a “hold” rating on the stock in a report on Wednesday, December 18th.

Institutional Trading of OrthoPediatrics

A number of institutional investors have recently modified their holdings of KIDS. Mutual of America Capital Management LLC boosted its holdings in shares of OrthoPediatrics by 195.1% in the 3rd quarter. Mutual of America Capital Management LLC now owns 107,609 shares of the company’s stock valued at $2,917,000 after buying an additional 71,146 shares in the last quarter. Quest Partners LLC raised its position in shares of OrthoPediatrics by 924.4% in the 3rd quarter. Quest Partners LLC now owns 11,986 shares of the company’s stock valued at $325,000 after purchasing an additional 10,816 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of OrthoPediatrics in the 3rd quarter valued at approximately $295,000. Charles Schwab Investment Management Inc. raised its position in shares of OrthoPediatrics by 2.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 132,434 shares of the company’s stock valued at $3,590,000 after purchasing an additional 2,661 shares during the last quarter. Finally, Quantbot Technologies LP raised its position in shares of OrthoPediatrics by 42.2% in the 3rd quarter. Quantbot Technologies LP now owns 5,773 shares of the company’s stock valued at $157,000 after purchasing an additional 1,712 shares during the last quarter. 69.05% of the stock is currently owned by institutional investors.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.